Clinical Significance of an IgM and IgG Test for Diagnosis of Highly Suspected COVID-19

Xingwang Jia, Pengjun Zhang, Yaping Tian, Junli Wang, Huadong Zeng, Jiao Liu, Zeyan Chen, Lijun Zhang, Haihong He, Kunlun He, Yajie LiuFrontiers in Medicine 2021 · DOI

Abstract

Quick, simple, and accurate diagnosis of suspected COVID-19 is essential for effective patient screening and therapy. While various diagnostic methods were deployed during the early pandemic, the specific diagnostic value of IgM and IgG antibodies required further clinical evaluation. This study analyzed 57 patients with highly suspected COVID-19 infection: 24 with positive nucleic acid tests and 33 with negative results. The positive detection rate for the combination of IgM and IgG was 87.50% in the nucleic acid-positive group and 72.73% in the nucleic acid-negative group. These results were significantly higher than those of nucleic acid testing or single antibody detection alone. Additionally, biochemical markers such as high-sensitivity C-reactive protein (hsCRP) and aspartate aminotransferase (AST) showed significant correlations with infection status. Our findings suggest that combined serological testing provides a rapid and accurate aided detection method for suspected patients and on-site screening.

Introduction

In the early stages of the COVID-19 pandemic, clinicians faced a significant diagnostic hurdle. The primary tool for identification—nucleic acid testing (RT-PCR)—exhibited notable limitations, including being time-consuming, prone to laboratory contamination, and highly dependent on the quality of the swab and the timing of the sample collection. Many patients presented with classic clinical symptoms, such as fever and respiratory distress, and "ground-glass opacities" (GGO) on CT scans, yet repeatedly returned negative PCR results.

This study evaluates whether serological testing, specifically measuring IgM and IgG antibodies, could serve as a faster and more sensitive "aided detection" method to fill the diagnostic gaps left by PCR, particularly for highly suspected cases and population screening.

Methods

The researchers conducted a retrospective study of 57 patients at Shenzhen Hospital who were classified as "highly suspected" of having COVID-19 based on epidemiological history, fever, respiratory symptoms, and CT imaging.

Serology and Baseline

To detect IgM and IgG, the team utilized a Time-Resolved Immunofluorescence Assay (Beijing Diagreat Biotechnologies). To establish a reliable baseline, they tested 242 healthy individuals, setting positive cutoffs at the 95th percentile of this healthy group (0.88 for IgM and 1.02 for IgG).

Biochemical Analysis

Beyond antibodies, the team analyzed nine biochemical indicators to identify correlations with infection status. These included:

  • High-sensitivity C-reactive protein (hsCRP)
  • White blood cell counts (WBC)
  • Liver enzymes (ALT and AST)

Results were cross-referenced against multiple rounds of pharyngeal swab nucleic acid tests and chest CT scans to determine the sensitivity and accuracy of the serological approach.

Key Insights and Results

The "Leaky" Gold Standard

The study highlights why PCR often fails as a standalone diagnostic. Viral loads are frequently higher in the nasal cavity than the throat, and the window for detection is narrow. For instance, one patient in the study tested negative via PCR 34 days after exposure but was clearly positive for IgM antibodies, illustrating the persistence of serological markers compared to viral RNA.

Serology as a Safety Net

The most striking finding was the performance of combined IgM/IgG testing in PCR-negative patients. Among the 33 patients who returned negative PCR results but were clinically ill, 72.73% were positive for antibodies. For those who were already PCR-positive, the combined antibody detection rate reached 87.50%. Statistical analysis confirmed that the combination of IgM and IgG was significantly more effective than either antibody test used in isolation ($P < 0.01$).

Biomarker Divergence and Liver Involvement

The research identified significant differences in inflammatory and liver markers:

  • hsCRP: Levels in the PCR-negative group were significantly higher (1.10 mg/L) than in the PCR-positive group (0.51 mg/L) ($P=0.0298$). This suggests that patients missed by PCR might be in a different inflammatory stage of the disease.
  • AST: Aspartate aminotransferase levels were significantly lower in the IgM-negative group compared to the positive group ($P=0.0365$). This supports the hypothesis that COVID-19, or the systemic inflammatory response it triggers, causes measurable liver injury as the infection progresses.

Discussion and Limitations

While the study provides strong evidence for serological testing, the authors acknowledge several constraints typical of early-outbreak research. The sample size of 57 patients is relatively small, which may introduce bias. Furthermore, antibody production (seroconversion) takes time; if a patient is tested too early after exposure, serological tests may return false negatives. Future research should involve longitudinal follow-ups to map the exact timeline of IgM and IgG appearance more precisely.

Conclusion

The paper argues for a holistic diagnostic approach. Relying on a single swab or a single testing modality is insufficient for pandemic control. By combining PCR, antibody testing, CT scans, and clinical symptoms, healthcare providers can significantly reduce the rate of missed diagnoses and improve the screening of close-contact populations.

Summary updated

Abstract

<b>Background:</b> Nucleic acid detection and CT scanning have been reported in COVID-19 diagnosis. Here, we aimed to investigate the clinical significance of IgM and IgG testing for the diagnosis of highly suspected COVID-19. <b>Methods:</b> A total of 63 patients with suspected COVID-19 were observed, 57 of whom were enrolled (24 males and 33 females). The selection was based on the diagnosis and treatment protocol for COVID-19 (trial Sixth Edition) released by the National Health Commission of the People's Republic of China. Patients were divided into positive and negative groups according to the first nucleic acid results from pharyngeal swab tests. Routine blood tests were detected on the second day after each patient was hospitalized. The remaining serum samples were used for detection of novel coronavirus-specific IgM/IgG antibodies. <b>Results:</b> The rate of COVID-19 nucleic acid positivity was 42.10%. The positive detection rates with a combination of IgM and IgG testing for patients with COVID-19 negative and positive nucleic acid test results were 72.73 and 87.50%, respectively. <b>Conclusions:</b> We report a rapid, simple, and accurate detection method for patients with suspected COVID-19 and for on-site screening for close contacts within the population. IgM and IgG antibody detection can identify COVID-19 after a negative nucleic acid test. Diagnostic accuracy of COVID-19 might be improved by nucleic acid testing in patients with a history of epidemic disease or with clinical symptoms, as well as CT scans when necessary, and serum-specific IgM and IgG antibody testing after the window period.
BibTeX
@inproceedings{jia2021clinical,
  author = {Xingwang Jia and Pengjun Zhang and Yaping Tian and Junli Wang and Huadong Zeng and Jun Wang and Jiao Liu and Zeyan Chen and Lijun Zhang and Haihong He and Kunlun He and Yajie Liu},
  title = {{Clinical Significance of an IgM and IgG Test for Diagnosis of Highly Suspected COVID-19}},
  booktitle = {Frontiers in Medicine},
  year = {2021},
  doi = {10.3389/fmed.2021.569266},
}
Figure